Drugs / INCAGN01949
INCAGN01949
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04387071 | Apr 2021 → Dec 2022 | high grade malignant neoplasm, pancreatic adenocarcinoma | University of Southern California | Terminated | No outcome recorded |
| Phase 1/2 | NCT03241173 | Oct 2017 → Sep 2019 | cancer | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02923349 | Oct 2016 → Mar 2019 | metastatic malignant neoplasm | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCAGN01949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03241173 ↗ |
| Known as | Anti-OX40 Agonist Antibody INCAGN01949 | “Anti-OX40 Agonist Antibody INCAGN01949” NCT04387071 ↗ |
| Known as | Monoclonal Antibody INCAGN01949 | “Monoclonal Antibody INCAGN01949” NCT04387071 ↗ |
| Action | Activate | “anti-OX40 agonist” PMID 36316061 ↗ Oct 2022 |
| Modality | Monoclonal antibody | “anti-OX40 agonist monoclonal antibody” PMID 36316061 ↗ Oct 2022 |
| Route | Intravenous | “INCAGN01949 administered intravenously (IV)” NCT03241173 ↗ |